{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:14:08Z","timestamp":1786115648795,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the relationship between the degree and duration of immunoparesis at diagnosis and poor prognosis in patients with newly diagnosed multiple myeloma (NDMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on the clinical data of 258 patients with NDMM, including the status and duration of immunoparesis and the influence of other factors on prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>91.5% of NDMM had varying degrees of immunoparesis. The median progression-free survival (PFS) was significantly shorter in the severe immunoparesis group than in the non-severe immunoparesis group (25 months vs. 34 months, P\u00a0=\u00a00.0149). The median PFS was significantly shorter in the groups with severe immunoparesis lasting \u2265 3, \u2265 6, and \u2265 12 months than in the group with non-severe immunoparesis lasting (P \u22640.05). Osteolytic lesions, 17p deletion\/mutation, hemoglobin &amp;lt; 85g\/L, and severe immunoparesis lasting \u2265 12 months were independent poor prognostic factors for PFS (all P &amp;lt; 0.05). Circulating plasma cells \u2265 2% and osteolytic lesions were independent poor prognostic factors for overall survival (OS) (all P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunoparesis at diagnosis and its duration are poor prognostic factors for PFS in patients with NDMM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1831800","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:44Z","timestamp":1785990284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of severe immunoparesis degree and duration on progression-free survival in newly diagnosed multiple myeloma: a retrospective cohort study of 258 patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Linlin","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Leukemia Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Leukemia Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Leukemia Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Leukemia Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Henan Medical University","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Lymphoma Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]},{"name":"Key Laboratory for Leukemia Molecular Diagnosis and Treatment in Xinxiang City","place":["Weihui, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.240762","article-title":"Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care","volume":"105","author":"Djebbari","year":"2020","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S409234","article-title":"A single center study investigating clinical outcomes of testing for multiple myeloma and immune deficiency at low globulin levels","volume":"14","author":"Ramasamy","year":"2023","journal-title":"J Blood Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16572","article-title":"Identification of patients with smouldering multiple myeloma at ultra\u2010high risk of progression using serum parameters: the Czech Myeloma Group model","volume":"190","author":"H\u00e1jek","year":"2020","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2016.0161","article-title":"The effect of suppressed levels of uninvolved immunoglobulins on the prognosis of symptomatic multiple myeloma","volume":"34","author":"Sar\u0131","year":"2017","journal-title":"Turk J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population","volume":"12","author":"S\u00f8rrig","year":"2017","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3574-4","article-title":"Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1855345","article-title":"Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients","volume":"62","author":"Geng","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.008","article-title":"Impact of etiological cytogenetic abnormalities on the depth of immunoparesis and survival in newly diagnosed multiple myeloma","volume":"22","author":"Caro","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284154","article-title":"Recovery of uninvolved heavy\/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection","volume":"109","author":"Lakhwani","year":"2023","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2547-7","article-title":"Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation","volume":"109","author":"Gao","year":"2019","journal-title":"Int J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(80)90097-5","article-title":"Suppression of polyclonal lmmunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis\u2019","volume":"17","author":"Pruzanski","year":"1980","journal-title":"Clin Immunol Immunopathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-8115.2025.07.001","article-title":"Dynamic changes and prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients","volume":"45","author":"Yan","year":"2025","journal-title":"J Shang Hai Jiao Tong Univ Med Sci"},{"key":"B22","article-title":"Clinical characteristics and prognostic value of immunoparesis in newly diagnosed multiple myeloma","volume":"33","author":"Chen","year":"2023","journal-title":"Chin J Health Lab Tec"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18182","article-title":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem\u2010cell transplantation is a prognostic marker of longer progression\u2010free survival and overall survival","volume":"198","author":"D\u00e1vila","year":"2022","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329378","article-title":"Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis","volume":"29","author":"Chen","year":"2024","journal-title":"Hematology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20211108-00783","article-title":"Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response","volume":"61","author":"Yin","year":"2022","journal-title":"Chin J Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2014.12.015","article-title":"Clinical implications of immune paresis in symptomatic multiple myeloma patients","volume":"35","author":"Zhou","year":"2014","journal-title":"Chin J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16488","article-title":"Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma","volume":"189","author":"Chakraborty","year":"2020","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:47Z","timestamp":1785990287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1831800"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1831800","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1831800"}}